GB-115
Cholecystokinin-4 antagonist
GB-115 (Cholecystokinin-4 antagonist) is a cognitive & mood research compound. A dipeptide CCK-B receptor antagonist developed in Russia. CCK-4 reliably induces panic in humans, so blocking that receptor is a rational anxiolytic target that doesn't touch GABA.
GB-115 quick facts
| Reported research dose | 6mg daily |
| Route | Oral / intranasal |
| Frequency | Not established — no dosing protocol has been characterised |
| Half-life | Not characterised in published human work |
| Forms | Oral, Nasal |
| Evidence level | Russian preclinical and early clinical work, little of it in English or peer-reviewed internationally |
Mechanistically appealing — a non-GABAergic anxiolytic without sedation or dependence would be genuinely useful. But essentially all the data sits in Russian-language literature that hasn't been independently replicated, and no Western trial exists. Interesting, unproven, and the dosing floating around online has no published basis.
How GB-115 works
A dipeptide CCK-B receptor antagonist developed in Russia. CCK-4 reliably induces panic in humans, so blocking that receptor is a rational anxiolytic target that doesn't touch GABA.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients, real endpoints, published in Russian, and largely without the blinding, randomisation or independent replication a Western regulator would require. That is genuinely more than nothing and genuinely less than a trial, and the honest read sits between the two.
📊 Correlative data
- Very limited use outside Russian research settings. There is almost no community record, which means the clinical tier above is effectively the entire human evidence base for it.
🧪 Theoretical / extrapolated
- A dipeptide cholecystokinin (CCK) antagonist developed at the Russian Institute of Pharmacology. CCK-B receptor activation provokes panic in humans experimentally, so blocking it is a coherent anxiolytic target.
- That mechanism is unusual and interesting — it addresses anxiety without touching GABA, so it predicts no sedation and no dependence liability. It also predicts a narrower effect, since it targets one specific panic pathway.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
GB-115 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- This group acts directly on established CNS receptors — GABA-B (phenibut), serotonergic and histaminergic (trazodone, doxepin), beta-adrenergic (propranolol), dopaminergic (cabergoline, apomorphine). These are pharmacological drugs, not research peptides, and the predicted problems are the known ones for each receptor.
- Phenibut is the one that needs saying plainly: it is physically addictive. GABA-B agonism produces tolerance within days of regular use, and withdrawal is genuinely severe — anxiety, insomnia, tremor, and in heavy users, psychosis and seizures. It is closer to a benzodiazepine than to a nootropic in this respect, and it is sold as though it were the latter.
- Propranolol blunts the physical symptoms of adrenaline. That predicts the useful effect and also the problem — it blunts the training response and masks hypoglycaemia.
- Dopamine agonists predict nausea, orthostatic hypotension and, at the doses used in Parkinson's, impulse-control problems. Cabergoline's half-life is very long, so effects persist well past a dose.
What has actually been reported
- Phenibut dependence and withdrawal are well documented in case reports and poison-centre data.
- Trazodone: sedation, orthostatic hypotension, and rarely priapism — which is a medical emergency.
- Abrupt propranolol cessation causes rebound tachycardia and hypertension. Do not stop a beta-blocker suddenly.
- Cabergoline at high cumulative doses is associated with cardiac valve changes; at the low doses used for prolactin this has not been shown.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- For phenibut, the only reliable mitigation is frequency: occasional use does not produce dependence, regular use does. There is no dose that makes daily use safe.
- Taper anything in this group rather than stopping abruptly.
- Take the first dose of anything with orthostatic effects at home, sitting down.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Prolactin if using cabergoline (it is usually why you are). Otherwise blood pressure and heart rate are the monitoring that matters.
Don't run this if
- You already take a sedative, a benzodiazepine, or drink regularly — the CNS depressant effects are additive and this is where respiratory depression comes from.
- You are on an antidepressant and considering trazodone — serotonergic combinations need a prescriber, not a forum.
The honest unknown
- Most of this group is well characterised for its licensed use. What is NOT characterised is the off-label use most people here are making of it, at doses and durations nobody studied.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get GB-115
Buy GB-115 at Disguised Alpha →GB-115 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What GB-115 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for GB-115 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
Get the complete breakdown for GB-115 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside GB-115
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anaemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 102 markers A–Z
GB-115 — frequently asked questions
What is GB-115?
GB-115 (Cholecystokinin-4 antagonist) is a cognitive & mood research compound. A dipeptide CCK-B receptor antagonist developed in Russia. CCK-4 reliably induces panic in humans, so blocking that receptor is a rational anxiolytic target that doesn't touch GABA.
Is the full GB-115 protocol on this page?
The reported research dose is on this page, along with how GB-115 works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of GB-115?
GB-115 has an approximate half-life of Not characterised in published human work, which is part of what determines how often it's dosed.
What forms does GB-115 come in?
GB-115 is available as: Oral, Nasal.
What's the evidence behind GB-115?
Current evidence level: Russian preclinical and early clinical work, little of it in English or peer-reviewed internationally. GB-115 is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact GB-115 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What GB-115 is used for
GB-115 appears under 1 goal in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.